Testing for Homologous Recombination Deficiency in Cancer: Diagnostic Strategies and Clinical Perspectives

In collaboration with AstraZeneca, the Association for Molecular Pathology (AMP) is pleased to present a three-part online learning experience! 

Homologous recombination deficiency (HRD) has emerged as a clinically significant biomarker in multiple cancer types such as ovarian, breast, pancreatic, and other cancers.

Identifying the HRD phenotype in a tumor can provide information about expected clinical outcome, response to specific therapies, and potential hereditary cancer risk.

This course will provide a comprehensive overview of the ways in which HRD is relevant to contemporary cancer care. The presenters will define HRD, describe clinical assays that have been used to detect it, and discuss scenarios in which HRD could affect patient care. The course has a special focus on interdisciplinary communication and teamwork between pathologists and clinicians. 

This Virtual Education Series consists of modules that can be completed in any order. This course contains pre-knowledge check questions, lectures, slide handouts, post-knowledge check questions, and a certificate of completion. 

Faculty

Ian Hagemann, MD, PhD Course Director Washington University School of Medicine in St. Louis	Eric Vail, MD Cedars-Sinai Medical Center	Katherine Fuh, MD, PhD University of California, San Francisco

Modules

Nuts and Bolts of Homologous Recombination
Speaker: Eric Vail, MD

Clinical Detection of Homologous Recombination Deficiency 
Speaker: Ian Hagemann, MD, PhD

Clinical Utility of HRD Testing: A Case Based Discussion
Speaker: Katherine Fuh, MD, PhD

Target Audience

Primary: Pathologists (molecular and non-molecular), laboratory geneticists, pathology trainees and fellows, clinical laboratory directors, and other laboratory professionals (managers and technologists)
Secondary: Oncologists (including medical and surgical oncologists), genetic counselors, clinical pharmacists, and other members of the oncology care team who would intersect with HRD testing

Modules were recorded on September 18, 2024; September 25, 2024; and October 1, 2024
Expire from Catalog: March 20, 2026

Learners will be awarded a Certificate of Attendance at the conclusion of the course. 
CME or CMLE credits are NOT available for this educational series.

This educational content was fully funded by AstraZeneca. The authors, reviewers, and editors of these educational materials have made extensive efforts to ensure that treatments, diagnostics, and discussions about medical practice are accurate and conform to the standards accepted at the time of publication. However, constant changes in information resulting from continuing research and clinical experience, reasonable differences in opinions among authorities, unique aspects of individual clinical situations, and the possibility of human error in preparing a series of educational  materials  mean that other sources of medical information may differ from the information on this site. 

This educational curriculum is not supported by CME points.